Ipamorelin Research Guide: Selective GH Secretagogue, Ghrelin Receptor Biology, and Body Composition Research

By Sam Smith

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) selective growth hormone secretagogue developed by Novo Nordisk in the 1990s. The compound binds the ghrelin receptor (GHS-R1a) on pituitary somatotrophs and triggers pulsatile growth hormone release without the off-target cortisol, prolactin, or appetite effects that complicate older GHRPs (GHRP-2, GHRP-6, hexarelin). Ipamorelin is most commonly used in research stacked with the GHRH analogue CJC-1295, pairing pulse-triggering (ipamorelin) with baseline-raising (CJC-1295) for a more complete approximation of physiological GH secretion.

This guide walks through what ipamorelin does to the body, how the selective ghrelin receptor agonism produces GH release without cortisol elevation, comparisons with sermorelin and tesamorelin, dosage and administration in research protocols, side effects including downsides documented in clinical research, the FDA regulatory history, effects on testosterone and body composition, and what researchers should look for when sourcing material. Every load-bearing claim links to its primary source in PubMed.

What is ipamorelin and how does it work?

Ipamorelin is a selective growth hormone secretagogue. According to the original Novo Nordisk PubMed-indexed paper, ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release, meaning it does not also raise cortisol, prolactin, ACTH, or appetite the way GHRP-2 and GHRP-6 do. According to a later PubMed-indexed pharmacology review, ipamorelin is a selective growth hormone secretagogue and agonist of the ghrelin receptor (GHS-R1a), with binding affinity in the low nanomolar range.

The selectivity comes from the structural design: the 5-amino-acid sequence binds the ghrelin receptor but not the related receptor populations that drive cortisol and prolactin release. This is the defining advantage of ipamorelin over the older GHRP class and makes it the GH secretagogue of choice for research where pure GH release is the desired endpoint without HPA-axis or appetite confound.

Mechanism: ghrelin receptor and GH release

Ipamorelin binds the GHS-R1a on pituitary somatotrophs and triggers Gq-coupled signal cascade involving PLC, IP3, and intracellular calcium elevation. The result is pulsatile GH release that mimics the natural growth hormone rhythm rather than the flat elevations produced by exogenous GH. Published research shows that the GHS Ipamorelin is able to exert a dynamic control effect on the somatotroph population, modulating cell-level GH output rather than overriding the natural pituitary rhythm.

Stacked with the GHRH analogue CJC-1295 (which raises baseline GH), ipamorelin amplifies the pulse component of the released GH pattern. This is the standard research stack for body composition and lean mass research.

Body composition and bone effects

The body composition effects of ipamorelin are GH-mediated: modest lean mass gain, modest reduction in fat mass, and improvements in bone mineral content with sustained dosing. Published research shows that Ipamorelin dose-dependently increased LGR from 42 microm/day in the vehicle group toward levels approaching normal physiology, supporting longitudinal bone growth in rodent models. Published research shows that treatment of adult female rats with the GHSs ipamorelin and GHRP-6 increases BMC, supporting potential applications in bone biology research alongside the body composition endpoints.

Effect sizes are modest compared with exogenous GH administration but the selective profile means the changes come without the side effects that broader GH replacement carries.

Does ipamorelin affect testosterone?

Ipamorelin does not directly affect the HPG axis or testosterone production. Unlike GHRH analogues that secondarily can shift gonadal axis function, ipamorelin’s selectivity means testosterone, LH, and FSH remain unchanged at standard doses. This is one of its advantages for research where the GH axis is the endpoint and gonadal axis effects would confound the analysis.

Can ipamorelin be used for weight loss?

Ipamorelin is not a weight-loss peptide in the GLP-1-agonist sense. The GH-mediated lipolysis it triggers produces gradual fat-mass reductions of 2-5 percent over months, paired with small lean mass gains. Compared with semaglutide (14.9% body weight reduction at 2.4 mg over 68 weeks) or tirzepatide (20.9% at 15 mg over 72 weeks), ipamorelin’s magnitude is much smaller. The compound is better positioned for body recomposition research than for primary weight loss endpoints. Stacked with tesamorelin in visceral-fat research protocols, the combination produces somewhat larger visceral fat reductions.

Ipamorelin vs sermorelin vs tesamorelin

The three peptides all support the GH axis but at different points:

• Sermorelin: GHRH 1-29 analogue, raises baseline GH from the pituitary, short half-life requiring daily evening dosing
• Tesamorelin: stabilised GHRH 1-44 analogue, raises baseline GH with longer half-life, FDA-approved for HIV lipodystrophy
• Ipamorelin: ghrelin receptor agonist (different receptor from sermorelin/tesamorelin), triggers pulse GH release, very selective without cortisol/prolactin effects

The receptor difference matters for stack design: ipamorelin + sermorelin or ipamorelin + tesamorelin engage two different receptors and produce additive effects. Ipamorelin + GHRP-6 would engage the same receptor and would not add meaningful effect. CJC-1295 + ipamorelin is the most common research stack.

Dosage and administration

Research protocols use ipamorelin at 100-300 μg per dose by subcutaneous injection, two to three times daily. Bedtime dosing aligns with the natural night-time GH pulse. The peptide is supplied as a lyophilised powder for reconstitution in bacteriostatic water. Half-life is short (around 2 hours), so multi-daily dosing is required for sustained GH-pulse activity. Stacked with CJC-1295, the combined dose pen often delivers 100 μg ipamorelin + 100 μg CJC-1295 per administration.

Side effects and downsides of ipamorelin

The selective profile means side effects are minimal compared with older GHRPs. Reported events in research protocols are limited to mild injection-site irritation, occasional transient water retention (consistent with low-dose GH effects), and rare reports of mild headache. The notable absence of cortisol elevation, prolactin elevation, and appetite stimulation (the main downsides of GHRP-6 and GHRP-2) is what distinguishes ipamorelin from the older class.

The practical downside is the short half-life that requires multi-daily dosing, plus the modest effect sizes that require months of consistent use to produce measurable body composition changes.

Why did the FDA ban ipamorelin?

The FDA did not “ban” ipamorelin in the literal sense; the peptide was added to the FDA 503A “do not compound” list along with several other GH-axis peptides in 2023. This means licensed compounding pharmacies in the United States cannot prepare ipamorelin for patient use. The peptide was never FDA-approved as a finished pharmaceutical (Novo Nordisk discontinued development before submitting an NDA), so the 503A action did not remove an approved product. Research-grade ipamorelin remains legal in Canada and the United States as a research chemical under research-use-only labelling. The compound is on the World Anti-Doping Agency prohibited list.

Is ipamorelin legal to buy?

Ipamorelin is legal in Canada and the United States as a research chemical sold under research-use-only labelling. It is not approved by Health Canada or the FDA as a finished pharmaceutical. The FDA 503A “do not compound” listing restricts pharmacy compounding but does not affect research-chemical sales. The peptide is on the WADA prohibited list for competitive athletes.

Sourcing for research

Reproducible GH-axis research depends on the integrity of the input material:

• Batch-specific Certificate of Analysis from an independent third-party laboratory
• HPLC purity confirmation at 98 percent or above, with chromatogram trace
• Mass spectrometry verification of the expected ~711 Da pentapeptide molecular weight
• Endotoxin and sterility testing for in vivo or cell-culture work

Reviv Peptides supplies research-grade ipamorelin and the CJC-1295 + ipamorelin blend. View the Ipamorelin 10mg product page, or view the CJC-1295 + Ipamorelin Blend.

Ipamorelin questions

What does ipamorelin do to the body?

Ipamorelin binds the ghrelin receptor on pituitary somatotrophs and triggers pulsatile growth hormone release. Downstream effects include modest lean mass gain, modest fat mass reduction, and improvements in bone mineral content with sustained dosing. The selective receptor binding means no cortisol, prolactin, or appetite effects.

What are the downsides or side effects of ipamorelin?

Minimal: mild injection-site irritation, occasional transient water retention, rare mild headache. The practical downsides are the short half-life requiring multi-daily dosing and modest effect sizes requiring months of consistent use for measurable changes.

Why did the FDA ban ipamorelin?

Ipamorelin was added to the FDA 503A “do not compound” list in 2023, restricting compounding-pharmacy preparation. It was never FDA-approved as a finished pharmaceutical. Research-grade material remains legal in Canada and the United States under research-use-only labelling.

Does ipamorelin affect testosterone?

No. Ipamorelin’s receptor selectivity means it does not affect the HPG axis. Testosterone, LH, and FSH remain unchanged at standard research doses.

What is the correct ipamorelin dosage?

Research protocols use 100-300 μg per dose by subcutaneous injection, two to three times daily. Bedtime dosing aligns with natural GH pulse. Half-life is short (~2 hours), so multi-daily dosing is required for sustained activity.

Key data point: Johansen et al. (1999, Growth) published the first selectivity data establishing Ipamorelin as the only GHRP with no significant cortisol, prolactin, or ACTH elevation at GH-releasing doses — a specificity not shared by GHRP-2 or GHRP-6, both of which produce dose-dependent cortisol and prolactin spikes that confound long-term research protocols.

Summary

Ipamorelin is the most selective growth hormone secretagogue in the research peptide category, binding the ghrelin receptor on pituitary somatotrophs without the off-target cortisol, prolactin, or appetite effects that complicate older GHRPs. The compound is most commonly stacked with the GHRH analogue CJC-1295 for combined pulse-and-baseline GH coverage in body composition research. Effects on lean mass, fat mass, and bone mineral content are modest but reliable with sustained dosing. The compound is not FDA-approved as a finished pharmaceutical and was added to the FDA 503A “do not compound” list in 2023; research-grade material remains legal in Canada and the United States under research-use-only labelling. It is on the WADA prohibited list.

All products sold by Reviv Peptides are for research and educational purposes only and are not intended for human consumption.